Literature DB >> 21298328

Fluorescence single particle tracking for the characterization of submicron protein aggregates in biological fluids and complex formulations.

Vasco Filipe1, Robert Poole, Marika Kutscher, Katrien Forier, Kevin Braeckmans, Wim Jiskoot.   

Abstract

PURPOSE: To evaluate the potential of fluorescence single particle tracking (fSPT) for the characterization of submicron protein aggregates in human serum, plasma and formulations containing human serum albumin (HSA).
METHODS: A monoclonal IgG was covalently labeled with a fluorescent dye and cross-linked with glutaraldehyde. IgG aggregates and fluorescent beads of 0.1 μm (control) were diluted in buffer, serum and plasma, and their size distributions were analyzed by fSPT and nanoparticle tracking analysis (NTA). In a separate experiment, IgG and HSA, fluorescently labeled with different dyes, were mixed and subjected to heat stress. The stressed sample was analyzed by fSPT using a dual color mode and by NTA.
RESULTS: The accuracy and precision of fSPT proved to be comparable to NTA. fSPT was able to successfully measure all the samples in buffer, serum and plasma. The average size of the cross-linked protein aggregates showed a slight increase in biological fluids. Moreover, fSPT analysis showed that a significant proportion of the aggregates formed by subjecting an IgG/HSA mixture to heat stress were composed of both proteins.
CONCLUSION: fSPT is a powerful technique for the characterization of submicron protein aggregates in biological fluids and complex formulations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21298328      PMCID: PMC3073042          DOI: 10.1007/s11095-011-0374-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  23 in total

1.  Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption.

Authors:  A Gessner; R Waicz; A Lieske; B Paulke; K Mäder; R H Müller
Journal:  Int J Pharm       Date:  2000-03-10       Impact factor: 5.875

Review 2.  Bioequivalence and the immunogenicity of biopharmaceuticals.

Authors:  Huub Schellekens
Journal:  Nat Rev Drug Discov       Date:  2002-06       Impact factor: 84.694

Review 3.  The use of asymmetrical flow field-flow fractionation in pharmaceutics and biopharmaceutics.

Authors:  Wolfgang Fraunhofer; Gerhard Winter
Journal:  Eur J Pharm Biopharm       Date:  2004-09       Impact factor: 5.571

Review 4.  Protein aggregation and bioprocessing.

Authors:  Mary E M Cromwell; Eric Hilario; Fred Jacobson
Journal:  AAPS J       Date:  2006-09-15       Impact factor: 4.009

Review 5.  Protein aggregation: pathways, induction factors and analysis.

Authors:  Hanns-Christian Mahler; Wolfgang Friess; Ulla Grauschopf; Sylvia Kiese
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

6.  Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b.

Authors:  Suzanne Hermeling; Liliana Aranha; J Mirjam A Damen; Monique Slijper; Huub Schellekens; Daan J A Crommelin; Wim Jiskoot
Journal:  Pharm Res       Date:  2005-10-03       Impact factor: 4.200

7.  Structure and conformation of intramolecularly cross-linked collagen.

Authors:  R Usha; T Ramasami
Journal:  Colloids Surf B Biointerfaces       Date:  2005-03-10       Impact factor: 5.268

8.  Mechanism of crosslinking of proteins by glutaraldehyde II. Reaction with monomeric and polymeric collagen.

Authors:  D T Cheung; M E Nimni
Journal:  Connect Tissue Res       Date:  1982       Impact factor: 3.417

9.  Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality.

Authors:  John F Carpenter; Theodore W Randolph; Wim Jiskoot; Daan J A Crommelin; C Russell Middaugh; Gerhard Winter; Ying-Xin Fan; Susan Kirshner; Daniela Verthelyi; Steven Kozlowski; Kathleen A Clouse; Patrick G Swann; Amy Rosenberg; Barry Cherney
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

10.  An enzyme-linked immunosorbent assay (ELISA) for quantitation of adducts of granulocyte-macrophage colony stimulating factor (GM-CSF) and human serum albumin (HSA) in stressed solution mixtures.

Authors:  R Kumarasamy; J Bausch; D Kopcha; S Patel; E McGonigle
Journal:  Pharm Res       Date:  1994-03       Impact factor: 4.200

View more
  11 in total

Review 1.  Protein particulate detection issues in biotherapeutics development--current status.

Authors:  Tapan K Das
Journal:  AAPS PharmSciTech       Date:  2012-05-08       Impact factor: 3.246

2.  Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics.

Authors:  Maryam Ahmadi; Christine J Bryson; Edward A Cloake; Katie Welch; Vasco Filipe; Stefan Romeijn; Andrea Hawe; Wim Jiskoot; Matthew P Baker; Mark H Fogg
Journal:  Pharm Res       Date:  2015-04       Impact factor: 4.200

Review 3.  In Vivo Stability of Therapeutic Proteins.

Authors:  Joachim Schuster; Atanas Koulov; Hanns-Christian Mahler; Pascal Detampel; Joerg Huwyler; Satish Singh; Roman Mathaes
Journal:  Pharm Res       Date:  2020-01-03       Impact factor: 4.200

Review 4.  Engineered nanomaterial uptake and tissue distribution: from cell to organism.

Authors:  Helene Kettiger; Angela Schipanski; Peter Wick; Jörg Huwyler
Journal:  Int J Nanomedicine       Date:  2013-08-27

5.  Detection and characterization of subvisible aggregates of monoclonal IgG in serum.

Authors:  Vasco Filipe; Robert Poole; Olubukayo Oladunjoye; Kevin Braeckmans; Wim Jiskoot
Journal:  Pharm Res       Date:  2012-03-31       Impact factor: 4.200

6.  On the role of specific interactions in the diffusion of nanoparticles in aqueous polymer solutions.

Authors:  Ellina A Mun; Claire Hannell; Sarah E Rogers; Patrick Hole; Adrian C Williams; Vitaliy V Khutoryanskiy
Journal:  Langmuir       Date:  2013-12-27       Impact factor: 3.882

Review 7.  Combined Dielectrophoresis and Impedance Systems for Bacteria Analysis in Microfluidic On-Chip Platforms.

Authors:  Cristina Páez-Avilés; Esteve Juanola-Feliu; Jaime Punter-Villagrasa; Beatriz Del Moral Zamora; Antoni Homs-Corbera; Jordi Colomer-Farrarons; Pere Lluís Miribel-Català; Josep Samitier
Journal:  Sensors (Basel)       Date:  2016-09-16       Impact factor: 3.576

8.  Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.

Authors:  Joana Costa-Gouveia; Elisabetta Pancani; Samuel Jouny; Arnaud Machelart; Vincent Delorme; Giuseppina Salzano; Raffaella Iantomasi; Catherine Piveteau; Christophe J Queval; Ok-Ryul Song; Marion Flipo; Benoit Deprez; Jean-Paul Saint-André; José Hureaux; Laleh Majlessi; Nicolas Willand; Alain Baulard; Priscille Brodin; Ruxandra Gref
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

9.  Amyloid-β protofibrils: size, morphology and synaptotoxicity of an engineered mimic.

Authors:  Anatoly Dubnovitsky; Anders Sandberg; M Mahafuzur Rahman; Iryna Benilova; Christofer Lendel; Torleif Härd
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

10.  Sizing nanomaterials in bio-fluids by cFRAP enables protein aggregation measurements and diagnosis of bio-barrier permeability.

Authors:  Ranhua Xiong; Roosmarijn E Vandenbroucke; Katleen Broos; Toon Brans; Elien Van Wonterghem; Claude Libert; Jo Demeester; Stefaan C De Smedt; Kevin Braeckmans
Journal:  Nat Commun       Date:  2016-09-22       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.